Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Challenges in the diagnosis of Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease and its
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?
KA Jellinger, AD Korczyn - Advances in Surgical and Medical …, 2023 - taylorfrancis.com
The clinical features of dementia with Lewy bodies (DLB) and Parkinson's disease dementia
(PDD) are similar and include dementia, cognitive fluctuations, and (visual) hallucinations in …
(PDD) are similar and include dementia, cognitive fluctuations, and (visual) hallucinations in …
Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies
KA Jellinger - Journal of neural transmission, 2018 - Springer
Dementia with Lewy bodies (DLB) and Parkinson's disease-dementia (PDD), although
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
sharing many clinical, neurochemical and morphological features, according to DSM-5, are …
The role of neuroimaging in Parkinson's disease
Parkinson's disease (PD) is a neurodegenerative disorder that affects millions of people
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …
worldwide. Two hallmarks of PD are the accumulation of alpha‐synuclein and the loss of …
Molecular imaging: design mechanism and bioapplications
Molecular imaging is a non-invasive method to image and analyze the concentration and
activity of functional biomolecules in cells or in vivo at molecular level, and plays an …
activity of functional biomolecules in cells or in vivo at molecular level, and plays an …
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa
The natural pattern of progression of Parkinson's disease is largely unknown because
patients are conventionally followed on treatment. As Parkinson's disease progresses, the …
patients are conventionally followed on treatment. As Parkinson's disease progresses, the …
In vivo cholinergic basal forebrain atrophy predicts cognitive decline in de novo Parkinson's disease
Abstract See Gratwicke and Foltynie (doi: 10.1093/brain/awx333) for a scientific commentary
on this article. Cognitive impairments are a prevalent and disabling non-motor complication …
on this article. Cognitive impairments are a prevalent and disabling non-motor complication …
Network imaging biomarkers: insights and clinical applications in Parkinson's disease
Parkinson's disease presents several practical challenges: it can be difficult to distinguish
from atypical parkinsonian syndromes, clinical ratings can be insensitive as markers of …
from atypical parkinsonian syndromes, clinical ratings can be insensitive as markers of …
Diagnostic biomarkers for Parkinson's disease at a glance: where are we?
Parkinson's disease (PD) is a neurodegenerative disorder whose aetiology remains unclear:
degeneration involves several neurotransmission systems, resulting in a heterogeneous …
degeneration involves several neurotransmission systems, resulting in a heterogeneous …
Retinal thinning associates with nigral dopaminergic loss in de novo Parkinson disease
Objective To analyze the relationship between retinal thinning and nigral dopaminergic loss
in de novo Parkinson disease (PD). Methods Forty-nine patients with PD and 54 age …
in de novo Parkinson disease (PD). Methods Forty-nine patients with PD and 54 age …